Maxim downgraded Immutep (IMMP) to Hold from Buy after the company’s Phase 3 study with Merck (MRK) of eftilagimod alfa in patients in first line non-small cell lung cancer was halted for futility.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Morning News Wrap-Up 3/13/26: Friday’s Biggest Stock Market Stories!
- Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
- Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study
- Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?
- Immutep downgraded to Neutral from Outperform at Baird